m+Medelevator.RU
← Поиск публикаций
The neuroradiology journal · 2025

Endovascular treatment of intracranial aneurysms with silk vista baby flow diverter: A systematic review and meta-analysis.

СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Hajikarimloo Bardia, Mohammadzadeh Ibrahim, Tos Salem M, Hashemi Rana, Habibi Mohammad Amin, Hasanzade Arman, Bana Sara, Hooshmand Mahdi, Ghorbanpouryami Fatemeh, Najari Dorsa, Hezaveh Ehsan Bahrami

Аннотация

BackgroundThe Silk Vista Baby (SVB) flow diverter (FD) is a stent designed for small vessels ranging from 1.5 to 3.5 mm. It is the only FD deliverable through a 0.017-inch microcatheter. This systematic review and meta-analysis aimed to assess the SVB utilization in intracranial aneurysms (IAs).MethodsFour electronic databases, PubMed, Scopus, Embase, and Web of Science, were searched from inception to November 5th, 2024.ResultsTen studies with 359 patients with 373 IAs were included. Our results revealed a pooled complete occlusion rate of 65% (95%CI: 43%-83%), a favorable outcome rate of 94% (95%CI: 83%-100%), and a morbidity rate of 4% (95%CI: 0%-11%). Our meta-analysis revealed a pooled in-stent thrombosis rate of 2% (95%CI: 1%-5%), side branch occlusion rate of 2% (95%CI: 0%-3%), intracerebral hemorrhage (ICH) rate of 2% (95%CI: 1%-4%), and device shortening rate of 4% (95%CI: 3%-6%). The subgroup analysis showed that the complete occlusion rate (≤6: 84% [95%CI: 49%-100%] vs >6: 58% [95%CI: 41%-73%], p < .001) was higher in studies with 6-month or lower follow-up duration, and the favorable outcome rate was higher in those with greater than 6-month duration (≤6: 84% [95%CI: 73%-93%] vs >6: 97% [95%CI: 82%-100%], p < .001).ConclusionSVB is an efficient and safe therapeutic option for managing IAs. We demonstrated that it is associated with promising clinical and radiological outcomes and low rates of complications.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты